OptiBiotix Health PLC Director's Dealing (6620D)
October 11 2018 - 2:00AM
UK Regulatory
TIDMOPTI
RNS Number : 6620D
OptiBiotix Health PLC
11 October 2018
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Director's Dealing
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high cholesterol, diabetes
and skin care, announces that it received notification on 10
October 2018 that Mrs Carol Anne Christie, wife of Mr Sean
Christie, a Non-Executive Director of the Company, acquired 125,000
ordinary shares in the Company on 10 October 2018, representing
0.15% of the Company's issued share capital, at a price of 80 pence
per share and will be held in the name of Mrs Carol Anne Christie.
Prior to the transaction, neither Mr Christie nor Mrs Christie held
ordinary shares in the Company.
Under the AIM Rules for Companies, Mrs Carol Anne Christie is
considered a related party and therefore this transaction or any
further transactions must be disclosed under the AIM Rules for
Companies.
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014 and the person who arranged
for release of this announcement on behalf of the Company was
Stephen O'Hara, Chief Executive.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash/ Scott Mathieson / Kate Bannatyne
(Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
----------------------------------------------------------------------------------------------
a. Name Carol Anne Christie
--------------------------------------- -----------------------------------------------------
2 Reason for notification
--------------------------------------- -----------------------------------------------------
a. Position/Status Wife of Mr Sean Christie, a Non-Executive
Director of the Company
--------------------------------------- -----------------------------------------------------
b. Initial notification/ Initial Notification
Amendment
--------------------------------------- -----------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------------------
a. Name OptiBiotix Health Plc
--------------------------------------- -----------------------------------------------------
b. LEI 213800UKYQFT941QHS14
--------------------------------------- -----------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
----------------------------------------------------------------------------------------------
a. Description of
the financial 125,000 ordinary shares of 2p each
instrument, type
of instrument
Identification ISIN: GB00BP0RTP38
Code
--------------------------------------- -----------------------------------------------------
b. Nature of the Purchase of 125,000 ordinary shares in the
transaction Company. Following the transaction, Mrs
Carol Anne Christie has an interest in 125,000
ordinary shares in the Company.
Mr Sean Christie holds options over 100,000
ordinary shares in the Company.
--------------------------------------- -----------------------------------------------------
c. Price(s) and volume(s) Price(s) per Volume(s)
share
--------------------------------------- ----------------------------
80p 125,000
---------------------------- --------------------
Aggregated information
- Aggregated Volume 125,000
d. - Price 80p
--------------------------------------- -----------------------------------------------------
e. Date of the transaction 10 October 2018
--------------------------------------- -----------------------------------------------------
f. Place of the transaction London Stock Exchange, AIM
--------------------------------------- -----------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHDBLFFVBFLFBX
(END) Dow Jones Newswires
October 11, 2018 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024